May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Identification of Genotype–restricted Anti–Toxoplasma gondii Antibodies Among Individuals Infected in an Epidemic
Author Affiliations & Notes
  • J. Vaudaux
    Jules Stein Eye Institute,
    David Geffen School of Medicine at UCLA, Los Angeles, CA
  • M.Z. Doymaz
    Pathology and Laboratory Medicine,
    David Geffen School of Medicine at UCLA, Los Angeles, CA
  • G.N. Holland
    Jules Stein Eye Institute,
    David Geffen School of Medicine at UCLA, Los Angeles, CA
  • C. Muccioli
    Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • C. Silveira
    Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • R. Belfort, Jr.
    Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • D.A. Bruckner
    Pathology and Laboratory Medicine,
    David Geffen School of Medicine at UCLA, Los Angeles, CA
  • F. Yu
    Jules Stein Eye Institute,
    David Geffen School of Medicine at UCLA, Los Angeles, CA
  • J.L. Jones
    Centers for Disease Control and Prevention, Atlanta, GA
  • M.E. Grigg
    Infectious Diseases, University of British Columbia, Vancouver, BC, Canada
  • Footnotes
    Commercial Relationships  J. Vaudaux, None; M.Z. Doymaz, None; G.N. Holland, None; C. Muccioli, None; C. Silveira, None; R. Belfort, Jr., None; D.A. Bruckner, None; F. Yu, None; J.L. Jones, None; M.E. Grigg, None.
  • Footnotes
    Support  CDC; Research to Prevent Blindness, Inc.
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 1128. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Vaudaux, M.Z. Doymaz, G.N. Holland, C. Muccioli, C. Silveira, R. Belfort, Jr., D.A. Bruckner, F. Yu, J.L. Jones, M.E. Grigg; Identification of Genotype–restricted Anti–Toxoplasma gondii Antibodies Among Individuals Infected in an Epidemic . Invest. Ophthalmol. Vis. Sci. 2004;45(13):1128.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:To identify genotype–restricted antibodies present in the serum of individuals infected during a T. gondii epidemic that was characterized by a high prevalence of ocular toxoplasmosis. Methods:We used an assay described by Kong and associates (J Infect Dis 2003;187:1484–95), which utilizes a series of polymorphic peptides derived from highly immunogenic T. gondii–secreted proteins. The peptides were used to distinguish serologically between infections caused by T. gondii Type II versus Type I/III. Blood specimens were obtained from 40 residents of Santa Isabel do Ivai, Brazil, the site of a recent epidemic of toxoplasmosis. The presence or absence of infection was confirmed using a commercially available immunofluoresence assay. Specimens were tested against the panel of peptides to detect genotype–restricted antibodies present in the serum of infected individuals. A Type I parasite had previously been isolated from the water supply that is believed to have been the source of all infections, based on epidemiological studies. Results:Among 22 T. gondii–infected individuals, 15 (68%) had assay results consistent with a Type I/III infection. Among 18 individuals without documented T. gondii infection, 1 (5%) had assay results consistent with a Type I/III infection. We did not find evidence of Type II infections in any individuals. Conclusions:Assay results support the epidemiologic evidence for a Type I infection in this outbreak. The assay appears to be a promising tool for population–based studies of T. gondii infections, and may contribute to a better understanding of the pathogenesis and the spectrum of the clinical manifestations of ocular toxoplasmosis.

Keywords: toxoplasmosis • clinical laboratory testing • microbial pathogenesis: clinical studies 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×